API and IP Newsletter
Contents Recent Paragraph-IV filings. General information Delhi High Court Awards ₹217 Crore In Lost Profits Damages To CCAI In Patent Infringement Suit Against Mobi Antenna Technologies USFDA gives nod to first interchangeable biosimilar for two rare diseases Intellectual Property T 2209/21- Aflofarm Vs Straw Man Recent Paragraph-IV filings. We follow Paragraph-IV filings at the USFDA website. On 13 May 2024, the FDA published a new list of P-IV filings. The complete list can be found here . Below three are the new P-IV submissions. # ANDA filing details Comments 1 Cenobamate/Tablets/12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg Brand: Xcopri/ 212839 Date of Submission 11 March 24 Number of ANDAs: 2 Cenobamate is used to treat a certain type of seizure disorder. Two companies filed ANDAs on NCE-1 date. MSN and Aurobindo imported innovator samples and might have started generic development long ago. They might have filed an ANDA on the NCE-1 date. The compound patent i